Sign In
Buy SRPT
$16.66
+0.420 (+2.59%)
At Close: Jun 04, 2026
3 Revolutionary Stocks I'd Buy Right Now Without Hesitation
10:00am, Tuesday, 22'nd Aug 2023
CRISPR Therapeutics is using a novel technique to develop innovative therapies. Sarepta Therapeutics is developing medicines targeting a difficult-to-treat disease.
Sarepta Therapeutics, Inc. (SRPT) Q2 2023 Earnings Call Transcript
09:57pm, Wednesday, 02'nd Aug 2023
Sarepta Therapeutics, Inc. (NASDAQ:SRPT ) Q2 2023 Earnings Conference Call August 2, 2023 4:30 PM ET Company Participants Francesca Nolan - IR Director Doug Ingram - President and CEO Louise Rodino-Kl
Sarepta Therapeutics (SRPT) Reports Q2 Loss, Misses Revenue Estimates
07:28pm, Wednesday, 02'nd Aug 2023
Sarepta Therapeutics (SRPT) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $1.89. This compares to loss of $2.65 per share a year ago.
Sarepta Therapeutics (SRPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
11:39am, Tuesday, 25'th Jul 2023
Sarepta Therapeutics (SRPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sarepta Therapeutics: 'Hold' Amid Market Myopia
05:49am, Thursday, 13'th Jul 2023
Sarepta reported a $516.8M loss in Q1 2023 but saw increased revenues ($253.5M) and holds $1.9B in assets. FDA's narrower approval for Elevidys impacted the stock but could expand with a successful co
3 Biotech Stocks to Sell Before They Damage Your Portfolio
05:33pm, Wednesday, 12'th Jul 2023
There are several reasons that investors should be cautious about buying or holding biotech stocks at this point. First, the Street is generally bearish on the sector lately.
Sarepta (SRPT) Sells Priority Review Voucher for $102M
11:35am, Thursday, 06'th Jul 2023
Sarepta (SRPT) sells its priority review voucher that was awarded following the FDA's approval to Elevidys gene therapy for treating DMD. The company will invest these proceeds into R&D.
Sarepta Therapeutics completes sale of priority review voucher for $102 million
08:37am, Wednesday, 05'th Jul 2023
Sarepta Therapeutics Inc. SRPT, -0.90% said Wednesday it has completed the sale of its Rare Pediatric Disease Priority Review Voucher for $102 million and will use the proceeds for R&D. Sarepta was aw
Sarepta Therapeutics to Present at Cowen's 2nd Annual RNA Therapeutics Summit
08:30am, Monday, 03'rd Jul 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fi
Sarepta Therapeutics' Stock Is Down 14% in 1 Month, So Why Does Wall Street Expect It to Rise 65%?
08:45am, Friday, 30'th Jun 2023
Sarepta recently secured conditional approval for its gene-editing therapy. But the therapy's high price tag might slow down its uptake among patients.
Sarepta CEO Doug Ingram: We should be profitable by the end of next year if we achieve our goals
12:21pm, Thursday, 29'th Jun 2023
Doug Ingram, Sarepta Therapeutics CEO, joins 'Squawk on the Street' to discuss the FDA's concerns with Sarepta's latest approval, how confident Ingram is the company's latest drug approval won't get r
Sarepta Therapeutics Gets FDA Nod, Drops Warning (or Opportunity?)
09:01am, Tuesday, 27'th Jun 2023
On May 15, Sarepta Therapeutics Inc. NASDAQ: SRPT learned that its treatment for Duchenne muscular dystrophy (DMD) was recommended for approval by the Food and Drug Administration (FDA) advisors. Natu
Sarepta (SRPT) Gets FDA's Accelerated Nod for DMD Gene Therapy
02:09pm, Friday, 23'rd Jun 2023
Following FDA???s approval, Sarepta's (SRPT) Elevidys becomes the first gene therapy for treating DMD.
Sarepta slumps as concerns emerge around upcoming gene therapy data
12:50pm, Friday, 23'rd Jun 2023
Sarepta Therapeutics shares slumped 11% on Friday as some analysts voiced concerns that upcoming confirmatory trial data for its gene therapy to treat Duchenne muscular dystrophy (DMD) may not be enou
Sarepta's Gene Therapy Approval Lands With a Thud
12:06pm, Friday, 23'rd Jun 2023
The $3.2 million one-time treatment is the first gene therapy approved to treat DMD, a progressive and fatal condition that manifests in early childhood.
